



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-DR5 [PRO95780 (Drozitumab)] Bulk Size Ab00740-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

**Isotype and Format:** Human IgG1, Fc Silent™, Lambda

**Clone Number:** PRO95780 (Drozitumab)

**Alternative Name(s) of Target:** death receptor 5; TRAIL receptor 2; TRAILR2; tumor necrosis factor receptor superfamily member 10B; TNFRSF10B; CD262; apomab

**UniProt Accession Number of Target Protein:** O14763

**Published Application(s):** agonist, functional/therapeutic, immunoblot, IP, ELISA, IF

**Published Species Reactivity:** Human

**Immunogen:** The variable domains of this antibody were derived as scFv from a human antibody phage display library, with biotinylated DR5-Fc used to capture DR5-specific phage. The scFv obtained were subsequently reformatted into full-length antibodies.

**Specificity:** This antibody is specific for human death receptor 5, a proapoptotic receptor widely expressed in adult and fetal tissues, with notably high expression on tumour cells. Activation of DR5 triggers apoptosis in various types of cancer cells, without affecting most normal cell types.

**Application Notes:** This antibody binds DR5, triggering DR5 clustering and DISC activation in a range of cancer cells, including colorectal cancer and NSCLC cells (Adams, 2009). Conversely, this antibody showed no effector caspase activation or cell death induction in normal human hepatocytes. In vivo, this antibody has been shown to inhibit tumor xenograft growth in a variety of animal models (Varfolomeev, 2009). This antibody was used in IP, immunoblot, ELISA and IF analysis to precisely characterise its interaction with the DR5 ligand (Adams, 2009).

**Antibody First Published in:** Adams et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ. 2008 Apr;15(4):751-61 [PMID:18219321](#)

**Note on publication:** Describes the generation of this antibody from a phage display library, and subsequent characterisation of its binding specificity.

### Product Form

**Size:**

1 mg Purified antibody in bulk size.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg /ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.